Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Cut by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 30.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 97,169 shares of the biopharmaceutical company's stock after selling 42,722 shares during the period. Victory Capital Management Inc. owned 0.09% of Regeneron Pharmaceuticals worth $61,627,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the company. Bryn Mawr Capital Management LLC purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $203,000. Tectonic Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 8.3% in the first quarter. Tectonic Advisors LLC now owns 899 shares of the biopharmaceutical company's stock worth $570,000 after buying an additional 69 shares during the last quarter. Concord Asset Management LLC VA raised its holdings in shares of Regeneron Pharmaceuticals by 75.5% in the first quarter. Concord Asset Management LLC VA now owns 2,259 shares of the biopharmaceutical company's stock worth $1,328,000 after buying an additional 972 shares during the last quarter. Leo Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 85.7% in the first quarter. Leo Wealth LLC now owns 1,179 shares of the biopharmaceutical company's stock worth $748,000 after buying an additional 544 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of Regeneron Pharmaceuticals by 37.6% in the first quarter. Massachusetts Financial Services Co. MA now owns 20,963 shares of the biopharmaceutical company's stock worth $13,295,000 after buying an additional 5,729 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. BMO Capital Markets cut their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating on the stock in a research note on Monday, June 2nd. Morgan Stanley dropped their price target on shares of Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating on the stock in a research report on Thursday, July 10th. Royal Bank Of Canada downgraded shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a report on Friday, May 30th. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Finally, Wells Fargo & Company downgraded shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the company from $700.00 to $580.00 in a report on Friday, May 30th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $823.54.

Regeneron Pharmaceuticals Trading Down 1.4%

Shares of NASDAQ REGN traded down $7.48 during midday trading on Friday, reaching $542.52. 1,307,803 shares of the stock were exchanged, compared to its average volume of 929,805. The company has a market capitalization of $58.57 billion, a P/E ratio of 13.81, a P/E/G ratio of 2.01 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The stock has a 50 day moving average price of $544.44 and a 200-day moving average price of $614.99.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the previous year, the firm posted $9.55 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 annualized dividend and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.